CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 295 enrolled
Drug / intervention
RTH258/Brolucizumabdrug
Likely dose
RTH258/Brolucizumab 6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04264819
NCT04264819Phase 3Completed
CompareCT.gov

A One-year, Single-arm, Open-label, Multicenter Study Assessing the Effect of Brolucizumab on Disease Control in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration (SWIFT)

Novartis Pharmaceuticals·interventional·Posted Feb 11, 2020·Updated Nov 7, 2024

In Brief

A Phase 3 clinical trial evaluating RTH258/Brolucizumab for Neovascular Age-Related Macular Degeneration. Completed, enrolled 295 participants across 51 sites.

Detailed Summary

Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid exudation, and fibrosis, resulting in photoreceptor damage and vision loss.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeovascular Age-Related Macular Degeneration
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 11, 2020
Enrollment StartDec 14, 2020
Primary CompletionOct 5, 2022
Study CompletionMay 10, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 6.4 years ago

Interventions

RTH258/Brolucizumabdrug

Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by Treat-to-Control regimen up to Week 44/46.